Y-mAbs Therapeutics A/S: Financial statements 2017
CVR: 37053678
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 13,194,221 and a net result of DKK -2,177,894. Equity in the 2017 report amounted to DKK 808,159. The solvency ratio was 7.4%.
- Gross Profit
- DKK 13,194,221
- Profit/Loss
- DKK -2,177,894
- Equity
- DKK 808,159
- Total Assets
- DKK 10,941,368
Official annual report
Keep an eye on Y-mAbs Therapeutics A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
Y-mAbs Therapeutics A/S has published its interim report for the period August 27, 2015 to December 31, 2016.
About Y-mAbs Therapeutics A/S
Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.